- Home
- LWAC vs IMMP Comparison
LWAC vs IMMP Comparison
Compare LWAC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAC
- IMMP
- Stock Information
- Founded
- LWAC 2025
- IMMP 1987
- Country
- LWAC United States
- IMMP Australia
- Employees
- LWAC N/A
- IMMP N/A
- Industry
- LWAC
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- LWAC
- IMMP Health Care
- Exchange
- LWAC Nasdaq
- IMMP Nasdaq
- Market Cap
- LWAC 299.8M
- IMMP 251.8M
- IPO Year
- LWAC 2025
- IMMP N/A
- Fundamental
- Price
- LWAC $9.94
- IMMP $1.69
- Analyst Decision
- LWAC
- IMMP Buy
- Analyst Count
- LWAC 0
- IMMP 1
- Target Price
- LWAC N/A
- IMMP $7.00
- AVG Volume (30 Days)
- LWAC 89.5K
- IMMP 87.2K
- Earning Date
- LWAC 01-01-0001
- IMMP 10-21-2025
- Dividend Yield
- LWAC N/A
- IMMP N/A
- EPS Growth
- LWAC N/A
- IMMP N/A
- EPS
- LWAC N/A
- IMMP N/A
- Revenue
- LWAC N/A
- IMMP $3,306,742.00
- Revenue This Year
- LWAC N/A
- IMMP N/A
- Revenue Next Year
- LWAC N/A
- IMMP $725.37
- P/E Ratio
- LWAC N/A
- IMMP N/A
- Revenue Growth
- LWAC N/A
- IMMP 31.28
- 52 Week Low
- LWAC $9.81
- IMMP $1.32
- 52 Week High
- LWAC $10.04
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- LWAC N/A
- IMMP 50.87
- Support Level
- LWAC N/A
- IMMP $1.60
- Resistance Level
- LWAC N/A
- IMMP $1.76
- Average True Range (ATR)
- LWAC 0.00
- IMMP 0.06
- MACD
- LWAC 0.00
- IMMP 0.01
- Stochastic Oscillator
- LWAC 0.00
- IMMP 58.82
About LWAC LightWave Acquisition Corp. Class A Ordinary Shares
LightWave Acquisition Corp is a blank check company.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.